MarketCapTrends
BGMS
Cyclacel Pharmaceuticals, Inc. (BGMS)
NASDAQ

Cyclacel Pharmaceuticals, Inc. Shareholder Equity 2009–2025

Cyclacel Pharmaceuticals, Inc. annual/quarterly shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Cyclacel Pharmaceuticals, Inc. shareholder equity for the quarter ending December 31, 2025 were 6.8M, a 414.72% decrease year-over-year.
  • Cyclacel Pharmaceuticals, Inc. shareholder equity for 2025 were 6.8M, a 414.72% decrease from 2024.
  • Cyclacel Pharmaceuticals, Inc. shareholder equity for 2024 were -2.2M, a 458.15% decrease from 2023.
  • Cyclacel Pharmaceuticals, Inc. shareholder equity for 2023 were 607,000, a 96.19% decrease from 2022.
  • Cyclacel Pharmaceuticals, Inc. shareholder equity for 2022 were 15.9M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Cyclacel Pharmaceuticals, Inc. Annual Shareholder Equity (Millions of US $)
2025$7
2024$-2
2023$1
2022$16
2021$38
2020$33
2018$15
2017$22
2016$14
2015$19
2014$22
2013$28
2012$10
2011$20
2010$25
Cyclacel Pharmaceuticals, Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$7
2024-12-31$-2
2023-12-31$1
2022-12-31$16
2021-12-31$38
2020-12-31$33
2018-12-31$15
2017-12-31$22
2016-12-31$14
2015-12-31$19
2014-12-31$22
2013-12-31$28
2012-12-31$10
2011-12-31$20
2010-12-31$25

Cyclacel Pharmaceuticals, Inc. Shareholder Equity — FAQ

Cyclacel Pharmaceuticals, Inc. (BGMS) shareholder equity over the last 16 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see BGMS's shareholder equity history?

The chart and table above show Cyclacel Pharmaceuticals, Inc.'s shareholder equity by year and by quarter, including the growth rate.